Breaking News

Sorrento to Acquire SmartPharm

Gains non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases.

By: Contract Pharma

Contract Pharma Staff

Sorrento Therapeutics, Inc. and SmartPharm Therapeutics, Inc. signed a letter of intent for Sorrento to acquire SmartPharm, a gene-encoded therapeutics company developing non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases, with broad potential for application in enhancing antibody-centric therapeutics. The transaction is expected to close in August 2020. Financial terms were not disclosed. The companies previously entered a R&D collaboration to encode and expres...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters